CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


PSC-04Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug2251 Prone positioning Wiki 0.58

Correlated MeSH Terms (3)


Name (Synonyms) Correlation
D000860 Hypoxia NIH 0.21
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0012418 Hypoxemia HPO 0.21

There is one clinical trial.

Clinical Trials


1 COVID-19 Stem Cell Therapy: A Phase I Study of Intravenous Administration of Allogeneic Adipose Stem Cells

This study is designed rapidly assess safety and preliminary efficacy in hospitalized patients with COVID-19 respiratory distress to provide clinical guidance for possible wider use in treating patients in this pandemic environment. This data will be used for FDA IND filings and pursuit of a BLA.

NCT04486001 Covid19 Biological: PSC-04

Primary Outcomes

Description: Frequency of all reported adverse events in study

Measure: Frequency of all adverse events

Time: Through study completion, an average of three months

Description: Frequency of SAEs in the 6 hours post-infusion for each infusion

Measure: Frequency of infusion related serious adverse events

Time: 6 hours post infusion

Description: Frequency of all serious adverse events in study

Measure: Frequency of serious adverse events

Time: Through study completion, an average of three months

Secondary Outcomes

Description: All-cause mortality through Day 28

Measure: Mortality

Time: Study days 0-28

Description: Ventilator free days through Study day 28

Measure: Ventilator Free Days

Time: Study days 0-28

Description: Total days not in ICU from Study day 0 through Study day 28

Measure: ICU Free Days

Time: Days 0 through 28

Description: Total Days in Hospital from Day 0 through discharge for survivors

Measure: Total Hospital Days

Time: Days 0 through discharge, an average of 28 days

Description: Total Days in ICU from Day 0 through discharge for survivors

Measure: Total ICU Days

Time: Days 0 through discharge, an average of 28 days

Description: Improvement in oxygenation comparing Study day 0, to days 2, 4, 6

Measure: Improvement in Oxygenation

Time: Study days 0, 2, 4, 6


No related HPO nodes (Using clinical trials)